Biomea Fusion, Inc. (BMEA) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-28

Key Insights

COVALENT-112 Phase 2 trial demonstrated a 52% increase in C-peptide AUC at Week 12 with icovamenib 200mg in early-stage Type 1 diabetes patients (0-3 years), with durability preserved through Week 52—a clinically significant result that could differentiate icovamenib from existing immunosuppressive approaches.
The study was conducted at only ~50% of originally intended enrollment due to an FDA clinical hold in May 2024 that was subsequently resolved, and the planned placebo-controlled Part 2 was not completed, limiting the robustness of efficacy claims pending full dataset presentation at ADA conference in June.
Company plans expansion to a Phase 2 trial in the second half of 2026 evaluating extended dosing (6-12 months) and combination with immunosuppressive agents across four leading U.S. academic diabetes centers, indicating confidence in advancement but requiring additional clinical validation.

Want the newest filings?

This analysis covers the filing from 2026-04-28. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-24

Biomea Fusion, Inc. reported its financial results for the quarter and year ended December 31, 2025, indicating that the company continued to progress its drug development pipeline.
The filing does not mention any material agreements, leadership changes, or other significant events that would impact the company's operations or future performance.
As an emerging growth company, Biomea Fusion has elected to take advantage of the extended transition period for complying with new or revised financial accounting standards, which could affect the comparability of its financial reporting.

Filed: 2026-02-25

Biomea Fusion updated its corporate presentation, which indicates the company is actively engaging with investors, analysts, and other third parties to share the latest information about its business.
The company is an emerging growth company and has not elected to use the extended transition period for complying with new or revised financial accounting standards, which suggests it is adhering to the latest reporting requirements.
Biomea Fusion's corporate presentation and SEC filing contain forward-looking statements about its ongoing research, development, and corporate partnering activities, which provide insight into the company's strategic priorities and future plans.

Filed: 2026-01-14

Biomea Fusion presented at the 44th Annual J.P. Morgan Healthcare Conference, showcasing their company and progress to investors.
The company updated their corporate presentation, indicating continued development and momentum in their research and clinical programs.
Biomea Fusion noted several forward-looking statements regarding the potential of their product candidates and development plans, suggesting ongoing activity and future catalysts.

Other reports for Biomea Fusion, Inc.

Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.